Trial Profile

A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Ciclosporin (Primary) ; Infliximab (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms CYSIF

Most Recent Events

04 Jan 2017 Results assessing long term outcomes from patients with steroid-refractory acute severe ulcerative-colitis published in the Gut.
10 Oct 2012 Results published in the Lancet.
10 Oct 2012 Primary endpoint 'Treatment-failure-rate' has not been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com